158 related articles for article (PubMed ID: 31201297)
1. Phospholipase C (PLC)ε Promotes Androgen Receptor Antagonist Resistance via the Bone Morphogenetic Protein (BMP)-6/SMAD Axis in a Castration-Resistant Prostate Cancer Cell Line.
Yuan M; Gao Y; Li L; Sun W; Cheng H; Li T; Niu L; Du Z; Quan Z; Luo C; Wu X
Med Sci Monit; 2019 Jun; 25():4438-4449. PubMed ID: 31201297
[TBL] [Abstract][Full Text] [Related]
2. Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
Sun W; Li L; Du Z; Quan Z; Yuan M; Cheng H; Gao Y; Luo C; Wu X
Oncol Rep; 2019 May; 41(5):2689-2702. PubMed ID: 30864728
[TBL] [Abstract][Full Text] [Related]
3. IAP Antagonists Enhance Apoptotic Response to Enzalutamide in Castration-Resistant Prostate Cancer Cells via Autocrine TNF-α Signaling.
Pilling AB; Hwang O; Boudreault A; Laurent A; Hwang C
Prostate; 2017 Jun; 77(8):866-877. PubMed ID: 28240376
[TBL] [Abstract][Full Text] [Related]
4. Study on the influence of metformin on castration-resistant prostate cancer PC-3 cell line biological behavior by its inhibition on PLCε gene-mediated Notch1/Hes and androgen receptor signaling pathway.
Yang Y; Wu XH
Eur Rev Med Pharmacol Sci; 2017 Apr; 21(8):1918-1923. PubMed ID: 28485785
[TBL] [Abstract][Full Text] [Related]
5. Knocking down SOX2 overcomes the resistance of prostate cancer to castration via notch signaling.
Du Z; Chen X; Zhu P; Lv Q; Yong J; Gu J
Mol Biol Rep; 2023 Nov; 50(11):9007-9017. PubMed ID: 37716921
[TBL] [Abstract][Full Text] [Related]
6. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
7. PLCε knockdown enhances the radiosensitivity of castration‑resistant prostate cancer via the AR/PARP1/DNA‑PKcs axis.
Pu J; Li T; Liu N; Luo C; Quan Z; Li L; Wu X
Oncol Rep; 2020 May; 43(5):1397-1412. PubMed ID: 32323799
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
[TBL] [Abstract][Full Text] [Related]
9. Bone morphogenetic protein-6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages.
Lee GT; Jung YS; Ha YS; Kim JH; Kim WJ; Kim IY
Cancer Sci; 2013 Aug; 104(8):1027-32. PubMed ID: 23710822
[TBL] [Abstract][Full Text] [Related]
10. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
11. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
Uemura H
Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction.
Lee GT; Kang DI; Ha YS; Jung YS; Chung J; Min K; Kim TH; Moon KH; Chung JM; Lee DH; Kim WJ; Kim IY
Br J Cancer; 2014 Mar; 110(6):1634-44. PubMed ID: 24518599
[TBL] [Abstract][Full Text] [Related]
13. Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo.
Liu J; Zhang R; Su T; Zhou Q; Gao L; He Z; Wang X; Zhao J; Xing Y; Sun F; Cai W; Wang X; Han J; Qin R; Désaubry L; Han B; Chen W
J Exp Clin Cancer Res; 2023 May; 42(1):128. PubMed ID: 37210546
[TBL] [Abstract][Full Text] [Related]
14. Rooibos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling.
Huang SH; Tseng JC; Lin CY; Kuo YY; Wang BJ; Kao YH; Muller CJF; Joubert E; Chuu CP
Phytomedicine; 2019 Nov; 64():153068. PubMed ID: 31419729
[TBL] [Abstract][Full Text] [Related]
15. Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression.
Li H; Xie N; Gleave ME; Dong X
Oncotarget; 2015 Aug; 6(24):20474-84. PubMed ID: 26009876
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin delays castration‑resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin‑1.
Gao Y; Li L; Li T; Ma L; Yuan M; Sun W; Cheng HL; Niu L; Du Z; Quan Z; Fan Y; Fan J; Luo C; Wu X
Int J Oncol; 2019 Jun; 54(6):2054-2068. PubMed ID: 31081050
[TBL] [Abstract][Full Text] [Related]
17. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
18. AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer.
Yin L; Ye Y; Zou L; Lin J; Dai Y; Fu Y; Liu Y; Peng Y; Gao Y; Fu Y; Qi X; Deng T; Zhang S; Li X
J Exp Clin Cancer Res; 2023 Aug; 42(1):204. PubMed ID: 37563661
[TBL] [Abstract][Full Text] [Related]
19. PLCε knockdown overcomes drug resistance to androgen receptor antagonist in castration-resistant prostate cancer by suppressing the wnt3a/β-catenin pathway.
Li L; Du Z; Gao Y; Tang Y; Fan Y; Sun W; Li T; Liu N; Yuan M; Fan J; Niu L; Yan J; Duan L; Wu X; Luo C
J Cell Physiol; 2019 Sep; 234(9):15472-15486. PubMed ID: 30684266
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of AP-1 transcription factors in human prostate LNCaP and PC-3 cells: role of Fra-1 in transition to CRPC status.
Kavya K; Kumar MN; Patil RH; Hegde SM; Kiran Kumar KM; Nagesh R; Babu RL; Ramesh GT; Chidananda Sharma S
Mol Cell Biochem; 2017 Sep; 433(1-2):13-26. PubMed ID: 28386843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
